NCT00167518View on ClinicalTrials.gov

Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

April 30, 2005

Conditions
Diabetic Macular Oedema
Interventions
DRUG

Triamcinolone acetate

Trial Locations (1)

2000

Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney, Sydney

All Listed Sponsors
lead

University of Sydney

OTHER

NCT00167518 - Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO) | Biotech Hunter | Biotech Hunter